Analyst Price Target is $27.75
▲ +131.06% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Annovis Bio in the last 3 months. The average price target is $27.75, with a high forecast of $36.00 and a low forecast of $9.00. The average price target represents a 131.06% upside from the last price of $12.01.
Current Consensus is
Moderate Buy
The current consensus among 4 contributing investment analysts is to moderate buy stock in Annovis Bio. This Moderate Buy consensus rating has held steady for over two years.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Read More